Affymetrix Adds New Tools for Targeted Genotyping Market to Accelerate Disease Studies
May 19 2011 - 5:50AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today launched new Axiom™
myDesign™ Targeted Genotyping (TG) Arrays for the targeted
genotyping market, enabling researchers to study mutations in
disease pathways and characterize gene-gene interactions. This
latest advancement allows researchers to design custom arrays to
genotype 1,500 to 2.6 million markers per sample and rapidly
transition from genome-wide scans to specific disease analyses with
different experimental approaches on the same platform. In addition
to Axiom myDesign TG Arrays, Affymetrix released a new version of
the Axiom™ Genomic Database containing 11 million variants, making
it the industry’s largest supply of validated genomic markers.
By expanding the scale of its Axiom Genomic Database and
utilizing the flexibility of the GeneTitan® System, Affymetrix
delivers a powerful customizable genotyping solution that eases
budget constraints and streamlines workflows. With this new
capability, researchers can leverage the Axiom™ Genotyping Solution
to explore regions of interest found in genome-wide association
studies (GWAS), validate novel SNPs from sequencing experiments, or
ramp up candidate gene projects with Axiom myDesign TG Arrays.
“Axiom myDesign TG Arrays will help researchers to quickly
evaluate interesting variants from their GWAS, sequencing and
candidate gene initiatives without limiting the number of markers
in their study," said Andy Last, Chief Commercial Officer of
Affymetrix. "Customers who want to add newly discovered content
after they complete the initial design can benefit from our new
flexible content capability without switching platforms.”
Researchers can use the Axiom™ Design Center to configure their
arrays using content from the Axiom Genomic Database or submit
their own sequence from SNP discovery. This convenient, online tool
allows researchers to select the most informative SNPs for their
study and work with the Affymetrix Bioinformatics Services team to
finalize their design.
The Axiom Genomic Database, with 11 million rare and common
variants with minor allele frequency (MAF) greater than 1 percent,
is derived from sources such as NHGRI, the International HapMap,
and 1000 Genomes Project. Each marker is annotated by MAF, linkage
disequilibrium (LD), and haplotype information, as well as SNP
classification and biological function. The database also contains
approximately 4 million SNPs associated with key processes or
pathways important to the study of pharmacogenomics genes,
cardiovascular disease, the human leukocyte antigen (HLA) region,
and inflammatory and immunity disease, as well as genes from the
Sanger Cancer Gene Census and previous association studies.
Axiom myDesign TG Arrays are available to configure and order
effective immediately. To learn more about Axiom myDesign Targeted
Genotyping Arrays and the new Axiom Genomic Database, please visit
www.affymetrix.com/mydesign.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
2,000 systems have been shipped around the world and more than
23,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Latin
America, and Asia. For more information about Affymetrix, please
visit http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,” “beliefs,” “hopes,”
“intentions,” “strategies” or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix’ Form 10-K for the
year ended December 31, 2010, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, Axiom, myDesign, and
GeneTitan are trademarks or registered trademarks of Affymetrix,
Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024